dc.contributor.author | Chandrasekhar, J. | |
dc.contributor.author | Baber, U. | |
dc.contributor.author | Sartori, S. | |
dc.contributor.author | Aquino, M. B. | |
dc.contributor.author | Hájek, P. | |
dc.contributor.author | Atzev, B. | |
dc.contributor.author | Hudec, M. | |
dc.contributor.author | Kiam Ong, T. | |
dc.contributor.author | Mates, M. | |
dc.contributor.author | Borisov, B. | |
dc.contributor.author | Warda, H. M. | |
dc.contributor.author | den Heijer, P. | |
dc.contributor.author | Wojcik, J. | |
dc.contributor.author | Iñiguez Romo, Andres | |
dc.contributor.author | Coufal, Z. | |
dc.contributor.author | Khashaba, A. | |
dc.contributor.author | Munawar, M. | |
dc.contributor.author | Gerber, R. T. | |
dc.contributor.author | Yan, B. P. | |
dc.contributor.author | Tejedor, P. | |
dc.contributor.author | Kala, P. | |
dc.contributor.author | Bang Liew, H. | |
dc.contributor.author | Lee, M. | |
dc.contributor.author | Kalkman, D. N. | |
dc.contributor.author | Dangas, G. D. | |
dc.contributor.author | de Winter, R. J. | |
dc.contributor.author | Colombo, A. | |
dc.contributor.author | Mehran, R. | |
dc.date.accessioned | 2022-05-19T08:33:31Z | |
dc.date.available | 2022-05-19T08:33:31Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 2352-9067 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/32953969 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/16741 | |
dc.description.abstract | Background: The COMBO stent is a biodegradable-polymer sirolimus-eluting stent with endothelial progenitor cell capture technology for faster endothelialization. Objective: We analyzed COMBO stent outcomes in relation to bleeding risk using the PARIS bleeding score. Methods: MASCOT was an international registry of all-comers undergoing attempted COMBO stent implantation. We stratified patients as low bleeding-risk (LBR) for PARIS score </= 3 and intermediate-to-high (IHBR) for score > 3 based on baseline age, body mass index, anemia, current smoking, chronic kidney disease and need for triple therapy. Primary endpoint was 1-year target lesion failure (TLF), composite of cardiac death, myocardial infarction (MI) not clearly attributed to a non-target vessel or clinically-driven target lesion revascularization (TLR). Bleeding was adjudicated using the Bleeding Academic Research Consortium (BARC) definition. Dual antiplatelet therapy (DAPT) cessation was independently adjudicated. Results: The study included 56% (n = 1270) LBR and 44% (n = 1009) IHBR patients. Incidence of 1-year TLF was higher in IHBR patients (4.1% vs. 2.6%, p = 0.047) driven by cardiac death (1.7% vs. 0.7%, p = 0.029) with similar rates of MI (1.8% vs. 1.1%, p = 0.17), TLR (1.5% vs. 1.6%, p = 0.89) and definite/ probable stent thrombosis (1.2% vs. 0.6%, p = 0.16). Incidence of 1-year major BARC 3 or 5 bleeding was significantly higher in IHBR patients (2.3% vs. 0.9%, p = 0.0094), as was the incidence of DAPT cessation (29.3% vs. 22.8%, p < 0.01), driven by physician-guided discontinuation. Conclusions: Patients with intermediate-to-high PARIS bleeding risk in the MASCOT registry experienced greater incidence of 1-year TLF, major bleeding and DAPT cessation than LBR patients, without significant differences in stent thrombosis. | en |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.title | 1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry | en |
dc.type | Journal Article | es |
dc.authorsophos | Chandrasekhar, J.;Baber, U.;Sartori, S.;Aquino, M. B.;Hájek, P.;Atzev, B.;Hudec, M.;Kiam Ong, T.;Mates, M.;Borisov, B.;Warda, H. M.;den Heijer, P.;Wojcik, J.;Iniguez, A.;Coufal, Z.;Khashaba, A.;Munawar, M.;Gerber, R. T.;Yan, B. P.;Tejedor, P.;Kala, P.;Bang Liew, H.;Lee, M.;Kalkman, D. N.;Dangas, G. D.;de Winter, R. J.;Colombo, A.;Mehran, R. | |
dc.identifier.doi | 10.1016/j.ijcha.2020.100605 | |
dc.identifier.pmid | 32953969 | |
dc.identifier.sophos | 40494 | |
dc.journal.title | IJC HEART & VASCULATURE | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Cardioloxía | es |
dc.page.initial | 100605 | es |
dc.rights.accessRights | openAccess | |
dc.subject.keyword | CHUVI | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 31. | es |